Lilly's tirzepatide led to greater improvements in liver fat content compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 MRI sub-study

Participants taking tirzepatide 15 mg experienced 47.11% relative reduction in liver fat content compared to 11.17% for insulin degludec Volume of abdominal adipose tissue decreased with tirzepatide, compared to an increase with insulin degludec INDIANAPOLIS , Sept.